What Элтацин Treats: Main Uses and Benefits

---

The medicine is considered relevant for managing symptoms related to heightened physiological activity and systemic imbalance. It may be part of symptomatic management for conditions involving episodic or fluctuating manifestations, such as Chronic Heart Failure (CHF) and Autonomic Dysfunction Syndrome. Additionally, it is applied in addressing symptomatic strain arising from chronic physical overexertion in active individuals. The therapeutic approach supports the body’s physiological resilience.

The primary goal is to provide supportive relief when symptoms interfere with routine activities. This supportive relief contributes to improved comfort during symptomatic periods, which may assist with maintaining functional stability.

“The medication is commonly used to help with symptom clusters that may become more disruptive during flare-ups in contexts requiring additional symptomatic support.”

Quick Fact: Support for Symptom Clusters

Symptom Domain	Patient Benefit	Use Context
Functional Cardiac Stress	May assist with symptoms related to physical discomfort (e.g., fatigue)	Adjunctive support for CHF symptoms
Systemic Imbalance	Supports the patient during episodes of systemic imbalance	Managing Autonomic Dysfunction
Physical Strain	Assists with managing symptoms that create noticeable physiological strain	Management of chronic overexertion

Who Can and Cannot Use Элтацин (Eltacin)

Eligibility for Элтацин, a combination of Glycine, L-Glutamic acid, and L-Cystine, is determined by official regulatory labeling, focusing on patient characteristics and physiological state.

Contraindications and Non-Eligibility

The medicine is contraindicated for patients with a known hypersensitivity to any of its active components or excipients. Furthermore, use is prohibited for children under the age of 11 years, as efficacy and safety have not been established in this younger age group according to regulatory documents.

Age-Specific Eligibility Rules

Age Group	Regulatory Status
Children (Under 11)	Contraindicated
Adolescents (11–18 years)	Permitted under restricted indications (e.g., specific heart conditions or chronic overexertion)
Adults (18+ years)	Permitted for labeled indications

Physiological Status Restrictions

Use is not recommended during pregnancy or while breastfeeding (lactation). This regulatory stance is based on the official determination that specific, separate safety studies in these populations have not been conducted.

The section on interactions is structured based on the comprehensive regulatory review of the active ingredients—Glycine, L-Glutamic acid, and L-Cystine. The primary finding across major government regulatory documents, including those published by the FDA and EMA, is the absence of explicit, formal interaction statements for this specific pharmaceutical combination.

---

Regulatory Status of Documented Interactions

The official interaction profile for Элтацин does not mandate specific constraints or requirements for co-administration with other medicines or substances. The lack of documentation means that standard regulatory classifications for interaction severity and mechanism are not applied in the official labeling.

Interaction Category	Official Regulatory Status
Contraindicated Combinations	None formally documented.
Exposure-Altering Interactions (PK)	No documented statements regarding pharmacokinetic changes (e.g., CYP or transporter effects).
Timing-Based Separation	No mandatory administration timing rules are documented due to interaction risk.
Food, Alcohol, Herbal Products	No specific interaction with food, alcohol, or herbal products is formally documented.
Pharmacodynamic Effects	No documented statements regarding additive or synergistic pharmacodynamic effects.

---

Profile Summary

The absence of detailed interaction information signifies that no mandatory restrictions, prohibitions, or specific administration guidelines related to drug-drug or drug-substance interactions are listed in the official government prescribing information. This structure contrasts with xenobiotic drugs and is typical for products composed of endogenous metabolites, where specific drug interaction studies often do not yield a formal interaction profile that requires regulatory constraint.

Элтацин is a combination of three non-essential amino acids: L-glycine, L-glutamic acid, and L-cystine. These molecular components function as metabolic regulators, primarily impacting cellular redox homeostasis.

L-cystine is rapidly reduced to L-cysteine post-administration. L-cysteine, along with L-glutamic acid and L-glycine, serves as the direct precursor for the intracellular biosynthesis of the tripeptide glutathione (GSH). By supplying these rate-limiting components, the compound elevates the intracellular concentration of GSH.

Elevated GSH levels act as a non-enzymatic antioxidant, neutralizing reactive oxygen species (ROS) and other electrophilic compounds. Furthermore, the increased GSH concentration enhances the activity of glutathione-dependent enzymes, such as glutathione peroxidase. This cascade modulates cellular oxidation-reduction processes by shifting the GSH/GSSG ratio toward the reduced form (GSH), thereby reducing oxidative stress at the cellular level. This mechanism results in systemic modulation of oxygen utilization and supports the synthesis of high-energy phosphate bonds, specifically adenosine triphosphate (ATP), which contributes to cellular energy dynamics across various tissues, including the myocardium.

How to Use Элтацин

This section outlines the standardized administration protocol for Элтацин, focusing on the dosage and usage patterns.

---

Administration Method and Timing

Элтацин is administered via the sublingual route, meaning the tablet is designed to be fully dissolved under the tongue. This method facilitates the absorption of the active components through the oral mucosa. The tablet must not be swallowed whole. A critical requirement for administration is the timing relative to food intake: the dose must be taken 20 minutes before a meal.

---

Dosage and Scheduling

Feature	Standardized Administration
Dosing Schedule	1 tablet (0.1 g total active substance) per dose
Frequency	Three times daily (t.i.d.)
Course Duration	A single course of treatment is typically 14 to 30 days

---

Use in Specific Age Groups

The standard 1 tablet three-times-daily regimen applies to adults and adolescents (12–18 years) when used for approved conditions. Use is also indicated for children aged 11 years and older for certain contexts. The use of this medicine is not established for children under 11 years of age. This defines the standardized dosage and frequency across applicable patient populations.

Research Evidence / Overview of Studies for Элтацин

The information below summarizes the available research concerning the clinical evaluation of Элтацин. It describes the types of studies conducted and what the findings reported, but it does not offer any clinical advice or interpretation of how the medicine may work for any individual.

---

Evidence for Use in Chronic Heart Failure (CHF) — Supportive Care

Research has studied this medicine, which is a specific combination of metabolic components, in the context of supportive care for patients dealing with Chronic Heart Failure (CHF). The studies were applied in research contexts involving fluctuating or unstable symptoms in a population often marked by conditions characterized by fluctuating or episodic manifestations.

The research included short-term randomized controlled trials (RCTs) focusing on the combination product, as well as broader studies exploring its individual amino acid components (which are metabolites). These studies monitored outcomes related to physical discomfort, such as fatigue levels, and measured changes in daily functioning or activity level. Researchers also monitored physiological markers related to heart function and metabolism.

Evidence for Use in Autonomic Dysfunction Syndrome

Элтацин was studied for its use in managing Autonomic Dysfunction Syndrome, which involves conditions involving periods of heightened symptoms related to the body's systemic control systems. Research in this area explored short-term symptom patterns in patients experiencing temporary physiological imbalance.

The studies largely focused on monitoring physiological markers of the autonomic nervous system, such as indices derived from Heart Rate Variability (HRV). These measures are intended to track outcomes related to systemic or functional imbalance. Studies also monitored patient-reported outcomes describing perceived discomfort related to instability.

---

What is Still Uncertain About the Research for Элтацин

A key limitation is the modest sample sizes and limited follow-up durations observed in many of the existing studies. Additionally, comparative evidence is lacking, which means there is limited information available on how the product compares to other established supportive treatments. The evidence quality varies across studies, and many findings rely on studies of the individual component amino acids rather than the specific, combined formulation. Overall, research is ongoing, and evidence highlights what is known — and what is still uncertain — about the clinical role of this metabolic support therapy.

Key Studies & References The Role of Amino Acid Glycine on Cardiovascular Health and Its Beneficial Effects: A Narrative Review

Common questions about Элтацин (FAQ)

---

Q: What is the main purpose of Элтацин?

According to official product information, Элтацин is indicated for specific health conditions. It is used in adults and children as an adjunctive therapy for chronic heart failure and for the syndrome of vegetative dysfunction. Additionally, in children, it is indicated for recovery after intense physical activity and for the prevention of chronic physical stress.

---

Q: Is Элтацин considered a vitamin, a supplement, or a medicine?

Regulatory documents classify Элтацин as a combined medicine. Its therapeutic category is officially listed as an antioxidant.

---

Q: What are the main conditions Элтацин is officially approved for?

The official label states that Элтацин is approved for conditions including chronic heart failure (NYHA functional classes I–III) and the syndrome of vegetative dysfunction. It also has an approval for use in children for the prevention of chronic physical stress and post-activity recovery.

---

Q: Why do people sometimes take Элтацин if they have heart concerns?

The official indication for Элтацин includes its use as part of basic therapy for chronic heart failure. Official documents state that the drug is described for its potential to support the contractility of the myocardium, which is the muscle tissue of the heart.

---

Q: What are the most commonly reported side effects of Элтацин?

The documented adverse reactions are limited to allergic reactions in the official product information.

---

Q: Can taking Элтацин cause feelings of nausea or stomach upset?

Official product information lists only allergic reactions as the documented adverse events. There is no specific mention in the regulatory documents of side effects like nausea or stomach upset.

---

Q: Do any official sources mention severe side effects for Элтацин?

The official label lists allergic reactions as the documented side effect. Furthermore, official records state that no cases of overdose have been identified.

---

Q: Is there a risk of becoming allergic to Элтацин?

According to official information, the drug is contraindicated for individuals who have a known hypersensitivity to its components. Allergic reactions are the documented adverse event listed in the safety profile.

---

Q: How long after taking a tablet does Элтацин remain active in the body?

Pharmacokinetic data from the regulatory label describes how the components move through the body. Specifically, one component, cystine, reaches its maximum concentration about 30 minutes after administration and then decreases gradually. The other components are noted as not accumulating in the tissues.

---

Q: Is Элтацин generally appropriate for older or elderly patients?

The official indications state that the drug is used in adults for chronic heart failure and vegetative dysfunction. The regulatory documentation does not include specific warnings or restrictions limiting its use in the elderly population.

---

Q: Are people with chronic kidney conditions generally allowed to take Элтацин?

Official data indicates that a small percentage (4–7%) of one component, glutamic acid, is excreted by the kidneys. However, the regulatory documents do not list chronic kidney conditions as a formal contraindication or include specific warnings against its use in such patients.

---

Q: Do the official documents list any specific diseases or conditions that forbid using Элтацин?

The official documents list two main contraindications. These are a known hypersensitivity to the drug's components and use in children younger than 11 years of age, as efficacy and safety have not been established in that group.

---

Q: What research evidence exists to support the use of Элтацин?

The official pharmacodynamics summary indicates that the drug is noted for its potential to support myocardium contractility and accelerate the recovery of physical capacity following intense physical activity, especially in children.

---

Q: Has Элтацин been studied for potential long-term benefits in patients?

While the label does not use the term 'long-term benefits', the official indications prescribe a typical treatment course of one to three months for chronic conditions. This suggests the drug has been studied for continuous, non-acute use over that specific duration.

---

Q: Why is Элтацин sometimes mentioned in the context of stress reduction or anxiety?

Official documentation indicates that the drug is approved for the syndrome of vegetative dysfunction. Additionally, in the context of chronic heart failure treatment, the drug is described as being associated with improvement in the psycho-emotional state of patients.

---

Q: Are there different forms or dosages of Элтацин available?

Official product information describes one formulation: a round flat cylindrical tablet containing a fixed composition of glycine, glutamic acid, and cystine. The official prescribing guidelines detail a standardized dosage and frequency for this single form.

---

Q: What are the main contraindications for Элтацин listed in regulatory documents?

According to regulatory documents, the two main reasons the drug should not be used are a known hypersensitivity to any of its components and for children under 11 years old, as the efficacy and safety have not been established for that age group.

---

Q: Why is Элтацин sometimes used to help with physical exercise tolerance?

Official product information states that the drug is indicated in children for the prevention of chronic physical stress and to accelerate recovery after intense physical activity. It is described as supporting physical capacity.

---

Q: Do doctors prescribe Элтацин for low energy or fatigue?

While not officially indicated using the terms 'low energy' or 'fatigue', the official label notes the drug's potential to support physical capacity. It also lists accelerated recovery after intense physical activity as one of its effects.

---

Q: What does the manufacturer's leaflet say about the appearance of the tablets?

The manufacturer's leaflet describes the product's appearance as a round, flat cylindrical tablet. The color is noted as being white to yellowish-white, and the tablets may exhibit elements of marbling.

---

Q: Is Элтацин the same as Glycine or other similar supplements?

Regulatory documents describe Элтацин as a combined medicine. It contains a mixture of three non-essential amino acids—glycine, L-glutamic acid, and L-cystine—and is therefore not the same as a single-ingredient Glycine product.

---

Q: Is it safe to take Элтацин with common over-the-counter painkillers?

Official drug interaction information explicitly states the medicine can be taken simultaneously with several classes of prescribed medicines. The regulatory document does not list any formal contraindications for co-administration with over-the-counter painkillers.

---

Q: What is known about the interaction between Элтацин and blood pressure medications?

The official label explicitly addresses this. It states that Элтацин can be taken simultaneously with several common classes of blood pressure medications, including ACE inhibitors, beta-blockers, and calcium channel blockers.

---

Q: Can Элтацин be taken simultaneously with other cardiac medicines?

The regulatory label explicitly permits this. Элтацин can be taken simultaneously with a number of key cardiac medicines, including ACE inhibitors, beta-blockers, diuretics, aldosterone antagonists, and organic nitrates.

---

Q: How does the listed mechanism of action of Элтацин relate to its primary use?

The drug's mechanism involves supplying precursors to increase the availability of glutathione and enhance the synthesis of ATP (cellular energy). This action is noted in official documents for its potential to support the contractility of the myocardium and increase overall physical capacity, which relates to its use in heart failure and physical stress conditions.

How to Store and Dispose of Элтацин

Official regulatory documents define strict environmental constraints for the storage and handling of Элтацин sublingual tablets to ensure stability and product integrity.

Required Storage Conditions

Requirement	Specific Condition
Temperature	Must not exceed 25 °C.
Protection	Store in a dry place, protected from light.
Packaging	Keep in the original packaging.
Child Safety	Must be stored out of reach of children.

Stability and Disposal

The product maintains an official shelf-life of 3 years and must not be used past the expiration date printed on the packaging. The medicine must be kept out of sight and reach of children. Official regulatory labeling does not provide specific instructions for the disposal of unused or expired Элтацин; disposal should follow local established pharmaceutical waste procedures.